中国组织工程研究 ›› 2022, Vol. 26 ›› Issue (32): 5126-5131.doi: 10.12307/2022.837

• 骨组织构建 bone tissue construction • 上一篇    下一篇

紫草素干预破骨细胞生成及破骨相关基因的表达

薄雨佳1,2,林  静1,2,王莉平1,2,赵  今1,2   

  1. 1新疆医科大学第一附属医院(附属口腔医院)牙体牙髓科,新疆维吾尔自治区乌鲁木齐市   830054;2新疆维吾尔自治区口腔医学研究所,新疆维吾尔自治区乌鲁木齐市   830054
  • 收稿日期:2021-10-08 接受日期:2021-11-09 出版日期:2022-11-18 发布日期:2022-05-12
  • 通讯作者: 赵今,主任医师,教授,新疆医科大学第一附属医院(附属口腔医院)牙体牙髓科,新疆维吾尔自治区口腔医学研究所,新疆维吾尔自治区乌鲁木齐市 830054
  • 作者简介:薄雨佳,女,1996年生,新疆维吾尔自治区五家渠市人,汉族,新疆医科大学在读硕士,主要从事天然药物防治牙周病研究以及牙体牙髓病研究。
  • 基金资助:
    国家重点实验室专项资金(SKLOD2021OF04),项目负责人:赵今

Shikonin intervenes with osteoclast formation and osteoclast-related gene expression

Bo Yujia1, 2, Lin Jing1, 2, Wang Liping1, 2, Zhao Jin1, 2   

  1. 1Department of Dentistry and Endodontics, First Affiliated Hospital (Affiliated Stomatological Hospital) of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China; 2Institute of Stomatology of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang Uygur Autonomous Region, China
  • Received:2021-10-08 Accepted:2021-11-09 Online:2022-11-18 Published:2022-05-12
  • Contact: Zhao Jin, Chief physician, Professor, Department of Dentistry and Endodontics, First Affiliated Hospital (Affiliated Stomatological Hospital) of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China; Institute of Stomatology of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang Uygur Autonomous Region, China
  • About author:Bo Yujia, Master candidate, Department of Dentistry and Endodontics, First Affiliated Hospital (Affiliated Stomatological Hospital) of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China
  • Supported by:
    the Special Funds of State Key Laboratories, No. SKLOD2021OF04 (to ZJ)

摘要:

文题释义:
牙周炎:是一种常见的多因素感染性疾病,可导致牙周支持组织的破坏,是造成成年人失牙的首要原因,严重影响患者的生活质量。目前临床上治疗牙周炎的方法主要是机械性清除菌斑、牙石并控制其他局部刺激因素,并应用药物作为机械性治疗的辅助治疗控制炎症、阻断牙槽骨吸收及促进骨再生。
紫草素:为紫色片状结晶或结晶性粉末,不溶于水,溶于乙醇、有机溶剂和植物油,易溶于碱水,遇酸又沉淀析出的性质,是存在于紫草中的一种萘醌类化合物,具有抗炎、抗病毒、抗肿瘤等作用。

背景:破骨细胞的活化在牙周炎的发生发展中起重要作用,紫草素因其毒副作用较小并具有抗炎等优点,可将其应用于牙周炎基础治疗后的辅助药物治疗。
目的:探讨紫草素对核因子κB受体活化因子配体(RANKL)诱导的破骨细胞生成及破骨相关基因表达的影响。
方法:采用CCK-8法检测不同浓度紫草素(0,0.062 5,0.125,0.25,0.5,1,2 μmol/L)对RAW264.7细胞的毒性,筛选出安全浓度;用不同质量浓度的核因子κB受体活化因子配体(0,30,50,100 μg/L)诱导RAW264.7细胞向破骨细胞分化,经抗酒石酸酸性磷酸酶染色观察破骨细胞数目,筛选出最佳核因子κB受体活化因子配体质量浓度;给予核因子κB受体活化因子配体和不同浓度的紫草素干预后,通过抗酒石酸酸性磷酸酶染色和抗酒石酸酸性磷酸酶活性检测其对破骨生成的影响;通过实时定量PCR技术检测破骨细胞标志性基因基质金属蛋白酶 9、组织蛋白酶K、核因子κB受体活化因子、活化T细胞核因子和原癌基因c-Fos的mRNA表达。
结果与结论:①高于0.5 μmol/L的紫草素显著抑制RAW264.7细胞的生长 (P < 0.05);② 50 μg/L的核因子κB受体活化因子配体为最佳诱导浓度;③紫草素呈浓度依赖性的抑制体外破骨细胞生成(P < 0.05);④紫草素呈浓度依赖性的抑制基质金属蛋白酶 9、组织蛋白酶K、核因子κB受体活化因子、活化T细胞核因子和原癌基因c-Fos等参与破骨细胞分化的标志性基因表达(P < 0.05);⑤结果表明,紫草素能够在体外呈浓度依赖性的通过抑制破骨相关基因的表达,进而抑制核因子κB受体活化因子配体诱导的破骨细胞的生成。
缩略语:核因子κB受体活化因子配体:receptor activator for nuclear factor-κB ligand,RANKL;核因子κB受体活化因子:receptor activator for nuclear factor-κB,RANK

https://orcid.org/0000-0002-9318-2469(薄雨佳) 

中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程

关键词: 紫草素, 破骨细胞生成, 牙周炎, RAW264.7, 核因子κB受体活化因子配体, 诱导, 活化T细胞核因子, 原癌基因c-Fos

Abstract: BACKGROUND: The activation of osteoclast plays an important role in the occurrence and development of periodontitis. In recent years, shikonin has been used as an adjuvant drug after periodontal non-surgical treatment because of its small side effects and anti-inflammatory properties.   
OBJECTIVE: To discuss the effects of shikonin on osteoclast formation induced by receptor activator for nuclear factor-κB ligand (RANKL) and osteoclast-related gene expression.
METHODS: The toxicity of different concentrations of shikonin (0, 0.062 5, 0.125, 0.25, 0.5, 1, and 2 μmol/L) to RAW264.7 cells was detected by cell counting kit-8 assay, and the optimal concentration was determined. RAW264.7 cells were induced into osteoclasts by different concentrations of RANKL (0, 30, 50, 100 μg/L). The number of osteoclasts was revealed by tartrate resistant acid phosphatase staining, and the optimal concentration of RANKL was determined. After treatment with different concentrations of shikonin, the effects of RANKL on osteoclast formation were detected by tartrate resistant acid phosphatase staining and tartrate resistant acid phosphatase activity. The mRNA expressions of osteoclast marker genes, including matrix metalloproteinase 9, cathepsin K, receptor activator for nuclear factor-κB, nuclear factor of activated T cells and proto-oncogene c-Fos, were detected by real-time quantitative PCR. 
RESULTS AND CONCLUSION: Shikonin at a concentration of higher than 0.5 μmol/L significantly inhibited the growth of RAW264.7 cells (P < 0.05). The optimal induction concentration of RANKL was 50 μg/L. Shikonin inhibited osteoclast formation in a concentration-dependent manner (P < 0.05). Shikonin also inhibited the expression of matrix metalloproteinase 9, cathepsin K, receptor activator for nuclear factor-κB, nuclear factor of activated T cells, and proto-oncogene c-Fos in a concentration-dependent manner (P < 0.05). To conclude, shikonin can inhibit RANKL-induced osteoclast formation by inhibiting the expression of osteoclast-related genes in a concentration-dependent manner in vitro.

Key words: shikonin, osteoclast formation, periodontitis, RAW264.7, receptor activator for nuclear factor-κB ligand, induction, nuclear factor of activated T cells, proto-oncogene c-Fos

中图分类号: